



27 January 2026

Control Bionics Signs Agreement with Tobii Dynavox to Evaluate Distribution Partnership in the United States

Melbourne, Australia – Control Bionics Limited (ASX: CBL) is pleased to announce that it has entered into an agreement with **Tobii Dynavox**, a global leader in Augmentative and Alternative Communication (AAC) solutions, to evaluate a distribution partnership by offering Control Bionics' **NeuroNode®** technology with its communication aids.

Tobii Dynavox will evaluate the NeuroNode for a six-month pilot period in five **states in the northwestern region of the United States**. NeuroNode replaces a previous partner of Tobii Dynavox in the United States.

The NeuroNode is designed to complement Tobii Dynavox's existing AAC solutions. Exploring **NeuroNode as a complement to Tobii Dynavox's established AAC portfolio could provide eye gaze users with another way to access their technology.**

Tobii Dynavox is widely recognised as a **global leader in the AAC market**, with a long history of delivering innovative access and communication solutions to individuals with communication disabilities. Control Bionics, meanwhile, has been a **pioneer in the use of surface electromyography (sEMG)** for more than two decades, enabling individuals to control technology through minimal muscle activation where traditional access methods may not be viable.

Control Bionics CEO, **Jeremy Steele**, said:

“Tobii Dynavox is a global leader in AAC, and we are pleased to be partnering with them to introduce NeuroNode into selected regions of the U.S. market. We believe this collaboration has the potential to meaningfully enhance how people access and use communication technology.

While this is an initial six-month pilot, we see real potential in the partnership, and we look forward to exploring the opportunity for a broader U.S. expansion over time.”

This ASX announcement has been approved for release by the CEO of Control Bionics Limited.

For further information, please contact:

Investors and Media:

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com

For further information visit the website: <https://www.controlbionics.com/>

About Control Bionics:

Control Bionics is a medical device company that has more than 20 years' experience in the development and use of surface Electromyography (EMG) devices.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

Control Bionics Limited

Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia
T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462